- $15.41bn
- $14.36bn
- $2.26bn
- 87
- 25
- 95
- 77
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 586 | 835 | 1,300 | 1,858 | 2,263 |
Cost of Revenue | |||||
Gross Profit | 427 | 618 | 904 | 1,312 | 1,682 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 786 | 1,042 | 2,067 | 2,670 | 2,673 |
Operating Profit | -200 | -206 | -767 | -812 | -410 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -210 | -266 | -850 | -801 | -337 |
Provision for Income Taxes | |||||
Net Income After Taxes | -209 | -266 | -848 | -815 | -355 |
Net Income Before Extraordinary Items | |||||
Net Income | -209 | -266 | -848 | -815 | -355 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -209 | -266 | -848 | -815 | -355 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.68 | -2.08 | -5.48 | -5.01 | -2.37 |